Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I

Document 2025-22763 is a Proposed Rule published by the Department of Justice in the Federal Register on December 15, 2025. The Administrator of the Drug Enforcement Administration is issuing this notification of intent to publish a temporary order to schedule 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][l, 4]diazepine (commonly known as bromazolam), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers are possible, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle bromazolam. View the original at https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i.

No. Document 2025-22763 is not classified as economically significant under Executive Order 12866. Economically significant rules require OIRA review and are estimated to have impacts of $100 million or more per year.